#United States #Cambridge #COVID-19 #Decoy Therapeutics #DCOY-CoV

Decoy Therapeutics and Once-Weekly Intranasal Dosing

Decoy Therapeutics, Inc., a pioneering biotechnology company specializing in Designable Multi-Antivirals (D-MAVs™), has announced a significant advancement in its DCOY-CoV program. The latest preclinical pharmacokinetic (PK) data demonstrates that a single intranasal dose of the DCOY-CoV therapy can sustain drug concentrations above therapeutic levels in both nasal mucosa and lung tissues for up to seven days. This breakthrough could change the landscape of antiviral treatment, especially for those at high risk of severe illness due to endemic coronaviruses.

Addressing a Critical Healthcare Need

The DCOY-CoV program specifically targets endemic human coronaviruses such as OC43, 229E, NL63, HKU1, and SARS-CoV-2—viruses known to present serious health threats to vulnerable populations, including over 20 million immunocompromised individuals and more than 15 million patients living with Chronic Obstructive Pulmonary Disease (COPD) in the United States and Europe. With current antiviral treatment options for these endemic viruses being extremely limited, the need for a novel solution has never been more pressing.

Dr. Michael Lipp, Chief Technology Officer of Decoy Therapeutics, presented these findings at the Boulder Peptide Symposium's Peptide Showcase. The data shed light on how a sustained therapeutic window can be achieved through innovative delivery methods that could enhance compliance among patients. By utilizing a design principle similar to subcutaneous GLP-1 therapies, Decoy Therapeutics engineered DCOY-CoV using its proprietary IMP3ACT™ platform, allowing for prolonged retention in target tissues.

Impressive Preclinical Findings

The preclinical studies affirm that a single intranasal administration of DCOY-CoV maintains pharmacologically active levels of the drug for seven days. This high degree of persistence in lung and respiratory tissues could offer critical protection against lower respiratory tract infections, which are known to be the leading cause of severe health complications associated with coronaviruses. The ease of once-weekly dosing could significantly improve adherence compared to daily oral or inhaled therapies, a major hurdle in patient treatment protocols.

Rick Pierce, the CEO of Decoy Therapeutics, emphasized the potential benefits of this approach, stating, “Most antivirals are designed for a singular virus, but D-MAVs target shared mechanisms across various viral families. We aim to provide patients with a convenient and effective option that meets significant unmet needs.”

Urgent Need for Effective Treatments

Endemic coronaviruses often result in mild symptoms for healthy individuals; however, they can trigger severe health crises for high-risk populations. Research indicates that about 40% of COPD exacerbations resulting in hospitalization are linked to these respiratory viruses. Furthermore, individuals hospitalized due to viral infections face significantly increased odds of intensive care admission and requirements for mechanical ventilation. Mortality rates following hospitalization can reach as high as 25% for those with certain viral infections, underscoring the urgency for effective preventative measures.

Dr. Barbara Hibner, Co-Founder and Chief Scientific Officer, highlights the importance of DCOY-CoV, expressing hopes for a breakthrough within the therapeutic landscape. “Our vision is to facilitate a simple, weekly dose that patients can self-administer without concern for daily regimens. This is especially vital for vulnerable groups, where respiratory viruses can induce irreversible lung damage,” she commented.

Future Outlook

As Decoy Therapeutics forges ahead, the DCOY-CoV program is anticipated to enter clinical trials in 2027, potentially changing the game in how we address endemic viral infections. The innovative use of AI-driven design, combined with advanced peptide-conjugate chemistry in the development of D-MAVs, positions Decoy Therapeutics at the forefront of the biotech industry, aiming to redefine treatment methodologies for endemic coronaviruses and beyond.

In conclusion, the preclinical findings from Decoy Therapeutics not only mark a promising advancement in antiviral therapy but could also provide vital protection for those most at risk in our communities. As the understanding of viral diseases evolves, so too does the importance of innovative treatment solutions like DCOY-CoV.